TMB Biomarker Is A Winding Path Rather Than Straight Road
Executive Summary
The tumor mutational burden biomarker had a much higher profile at this year's ASCO meeting, promising to help target treatment to individuals, though practical barriers remain and testing still is not ready for prime time yet.
You may also be interested in...
Merck's Keytruda Is First Checkpoint Inhibitor To Win US Approval Based On TMB Biomarker
Merck has secured FDA approval for Keytruda for use in tumors with high tumor mutational burden, something Bristol's Opdivo and AstraZeneca's Imfinzi were not able to do in lung cancer.
Keeping Track: Bad News For Bristol And Lilly, Good News For TG Therapeutics
The latest drug development news and highlights from our US FDA Performance Tracker.
Bristol Stuck In Waiting Game As Opdivo TMB Gamble Fails To Pay Off
Withdrawal of filing of CheckMate 227 data in patients with high tumor mutational burden (TMB) means another delay for Opdivo in first-line lung cancer.